Journal des maladies infectieuses et de la thérapie

Abstrait

Efficacy of Ceftolozane/Tazobactam in Infections with Multidrug-Resistant Gram-Negative Bacteria: A Preliminary Clinical Experience in a Highly Endemic Hospital

Lucia Brescini, Sara Mazzanti, Luca Battistelli, Gianluca Morroni, Francesco Pallotta, Bianca Candelaresi, Silvia Olivieri, Francesco Ginevri, Francesco Ginevri, Giulia Cesaretti, Raffaella Donati, Matteo Cimatti, Rosaria G Polo, Vanessa Di Muzio, Michele Di Prinzio, Oriana Cornacchini, Marcello Tavio, Andrea Giacometti, Abele Donati, Elisabetta Cerutti, Francesco Barchiesi

Introduction: Ceftolozane/Tazobactam is a new cephalosporin/beta-lactams inhibitor combination proven to be a drug with efficacy against urinary tract infections, abdominal infections and nosocomial ventilator-associated pneumonia, supported by multi-resistant Gram-negative bacteria.

Methods: This retrospective study considerated a cohort of 85 patients (≥ 18 years ), with a Gram-negative infection diagnosed between October 2017 and December 2020, treated with at least 72 hours of C/T therapy. The aim was to evaluate the efficacy, tolerability and to analyze any factors associated with a negative outcome.

Results: The clinical success achieved in patients treated with ceftolozane/tazobactam in this coorte was 59%. Risk factors independently associated with mortality were neutropenia (p=0.02) and ICU stay (p=0.009). High mortality in ICU is related to complexity of patients with multiple devices and concomitant infections that needed combination of antibiotic therapy.

Conclusion: Ceftolozano/tazobactam represents a therapy of choice in infections by Gram-MDR bacteria, also in that which multiple comorbidity and long hospital stay.